Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$18.17
$18.16
$8.00
$21.70
$1.85B1.45361,806 shsN/A
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
$18.88
$18.88
$8.39
$19.12
$1.58B2.645.12 million shsN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$1.17
+1.8%
$0.99
$0.69
$3.94
$231.89M0.74.83 million shs2.32 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$114.39
+0.6%
$108.41
$85.18
$129.90
$2.21B0.84118,156 shs52,056 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
0.00%0.00%0.00%0.00%0.00%
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
0.00%+17.85%+0.95%-4.80%-50.38%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.00%+0.21%+9.80%+14.88%+38.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
4.2225 of 5 stars
3.43.00.03.92.61.70.6
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4.8133 of 5 stars
3.53.00.04.42.73.31.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
0.00
N/AN/AN/A
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
0.00
N/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.80
Moderate Buy$7.00497.78% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$146.1427.76% Upside

Current Analyst Ratings Breakdown

Latest LGND, ALDR, AKCA, and ESPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/9/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.00
5/7/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.00
4/10/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$143.00
4/8/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$488.54M3.78$0.51 per share35.54$5.78 per share3.14
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
$1.62M977.10N/AN/A$1.61 per share11.73
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$332.31M0.70$0.02 per share48.70($1.97) per share-0.59
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$167.13M13.20$1.60 per share71.31$43.95 per share2.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/A
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$51.74M-$0.80N/AN/AN/A-59.03%-0.91%-29.47%8/11/2025 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-$4.03M-$7.12N/A30.83N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)

Latest LGND, ALDR, AKCA, and ESPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million
5/6/2025Q1 2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$0.18-$0.21-$0.03-$0.21$54.97 million$65.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/AN/A
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
N/AN/AN/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/A
12.17
11.78
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
1.74
8.94
8.94
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.18
0.81
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
5.27
5.02

Institutional Ownership

CompanyInstitutional Ownership
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
19.27%
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
N/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
248101.60 millionN/AOptionable
Alder Biopharmaceuticals Inc stock logo
ALDR
Alder Biopharmaceuticals
20283.84 millionN/AOptionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200198.20 million194.83 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.29 million17.94 millionOptionable

Recent News About These Companies

Ligand Pharmaceuticals Incorporated (LGND) - Yahoo Finance
Ligand Announces 2025 Investor Day in New York City

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akcea Therapeutics stock logo

Akcea Therapeutics NASDAQ:AKCA

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Alder Biopharmaceuticals stock logo

Alder Biopharmaceuticals NASDAQ:ALDR

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

$1.17 +0.02 (+1.83%)
Closing price 07/3/2025 03:42 PM Eastern
Extended Trading
$1.16 -0.01 (-0.51%)
As of 07/3/2025 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$114.38 +0.73 (+0.64%)
As of 07/3/2025 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.